Rigel Pharmaceuticals Reports Q2 2026 Financial Results

What Happened

• Rigel Pharmaceuticals, Inc. announced certain financial results for the quarter ended June 30, 2026 and furnished a press release titled “Rigel Reports Second Quarter 2026 Financial Results.” The company filed a Form 8-K on August 4, 2026 to report these results (Item 2.02).

Key Details

• Form 8-K filed: August 4, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Second quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 with the Form 8‑K.
• Report signed by Raymond J. Furey, Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary.

Why It Matters

• Quarterly financial results are material for investors because they provide updated information on the company’s earnings, revenue, expenses and cash position. Rigel’s press release (Exhibit 99.1) is the primary source for the specific figures and any commentary on performance or outlook; investors should review that release to assess near‑term financial health and any implications for valuation or investment decisions.